Sign in
TerminatedPhase 1/2

A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease

Key facts

Who runs it
University of Illinois Chicago
Where
Chicago, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
12 people enrolled
Started
16 Mar 2021
Ended
7 Oct 2024
Type of study
Interventional, 2 groups
Treatments tested
  • Voxelotor
Record updated
3 April 2025
Why it stopped
Sponsor voluntarily suspended distribution and removed product from the market

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Documentation of SCA genotype (HbSS or HbSβ0-thalassemia) may be based on history of laboratory testing or must be confirmed by laboratory testing during screening
  • Participants have had urine dipstick defined hemoglobinuria (positive for blood (+1 or higher) and ≤ 2 red blood cells per high power field) on 2 prior outpatient visits
  • Participants with albuminuria (urine albumin ≥ 30 mg/g creatinine) and an eGFR ≥ 60 mL/min/1.73m2 calculated using the CKD-EPI equation on 2 prior outpatient visits
  • Age ≥18 years
  • Hemoglobin (Hb) ≥ 5.5 and ≤ 10.0 g/dL during screening
  • For participants taking hydroxyurea (HU), the dose of HU (mg/kg) must be stable for at least 90 days prior to signing the ICF and with no anticipated need for dose adjustments or initiation during the study, in the opinion of the Investigator
  • Endari stable dose for one month
  • For participants taking an angiotensin converting enzyme (ACE)-inhibitor or angiotensin receptor blocker, the dose must be stable for at least 90 days prior to signing the ICF and with no anticipated need for dose adjustments or initiation during the study, in the opinion of the Investigator
  • Participants, who if female and of child bearing potential, are using highly effective methods of contraception from study start to 30 days after the last dose of study drug, and who if male are willing to use barrier methods of contraception, from study start to 30 days after the last dose of study drug
  • Participant has provided documented informed consent (the informed consent form [ICF] must be reviewed and signed by each participant

Who cannot take part

  • Patients who are receiving regularly scheduled blood (RBC) transfusion therapy (also termed chronic, prophylactic, or preventive transfusion) or have received a RBC transfusion for any reason within 30 days of signing the ICF or at any time during the screening period
  • Hospitalized for sickle cell crisis or other vaso-occlusive event within 14 days prior to signing the ICF (i.e., a vaso-occlusive event cannot be within 14 days prior to ICF)
  • History of unstable or deteriorating cardiac or pulmonary disease within 6 months prior to consent including but not limited to the following:; Unstable angina pectoris or myocardial infarction or elective coronary intervention; Congestive heart failure requiring hospitalization; Uncontrolled clinically significant arrhythmias
  • Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable)
  • Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational agent (or medical device)
  • Participants with clinically significant bacterial, fungal, parasitic or viral infection which require therapy:; Participants with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed; Participants with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive
  • History of malignancy within the past 2 years prior to treatment Day 1 requiring chemotherapy and/or radiation (with the exception of local therapy for non-melanoma skin malignancy)
  • Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, confound study interpretation, interfere with compliance, or preclude informed consent
  • Hepatic dysfunction characterized by alanine aminotransferase (ALT) >4 × ULN
  • Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit; calculated by the central laboratory) < 60mL/min/1.732, on chronic dialysis, or have received a kidney transplantation
  • Female who is breast feeding or pregnant
  • Inadequate venous access as determined by the investigator/site staff
  • Receipt of erythropoietin or other hematopoietic growth factors within 28 days of signing ICF or anticipated need for such agents during the study

Where in United States

  • University of IllinoisChicago, United States

About the trial

What the trial wants to find out

This study is a single center, prospective exploratory pilot study of Sickle Cell Anemia (SCA) participants. The study will enroll patients with early stages of sickle cell nephropathy (Chronic Kidney Disease (CKD) stage 1 or 2) who are at the highest risk of CKD progression (presence of both hemoglobinuria and urine albumin concentration ≥ 30 mg/g creatinin

The 2 groups in the trial

  • VoxelotTreatment being tested

    Voxelotor 1500mg once a day

    Treatment: Voxelotor

  • Standard of Care (SOC)Other group

    Observational while receiving SOC

    Treatment: Voxelotor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study of Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
Publications
Record updated
3 April 2025